Cecilia Brown

DocwireNews

The Food and Drug Administration (FDA) has granted accelerated approval to tarlatamab-dlle (Imdelltra) for patients with extensive stage small cell lung cancer (ES-SCLC) who have disease progression on or after platinum-based chemotherapy.
The treatment “is the first-and-only bispecific T-cell engager therapy for advanced SCLC,” according to Amgen, the manufacturer of the drug.
The efficacy of the treatment was evaluated in DeLLphi-301, an open-label, multicenter, multicohort study that included 99 patients who had relapsed or refractory ES-SCLC with disease progression after platinum-based chemotherapy. The patients received tarlatamab-dlle until disease progression or unacceptable toxicity.
The major efficacy outcome measures were the overall response rate (ORR) and duration of response (DOR), as assessed by blinded independent central review. The ORR was 40%, with a median DOR of 9.7 months. Among the 69 patients who had available data regarding platinum sensitivity status, the ORR was 52% in 27 patients with platinum-resistant SCLC and 31% in 42 patients with platinum-sensitive SCLC.
The most common adverse reactions were cytokine release syndrome (CRS), fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia, and nausea.
The most common grade 3 or 4 laboratory abnormalities were decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium.
The prescribing information for tarlatamab-dlle includes a boxed warning for serious or life-threatening CRS and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome.
The recommended dose is an initial dose of tarlatamab-dlle 1 mg administered as an intravenous infusion over 1 hour on day 1 of cycle 1, followed by 10 mg on days 8 and 15 of cycle 1, then every 2 weeks thereafter until disease progression or unacceptable toxicity.
The full prescribing information for tarlatamab-dlle will be posted <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm">here</a>.
Source: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer">FDA</a>

Andrew Moreno

Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow

ASH 2024

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line Treatment of ES-SCLC

Small Cell Lung Cancer

Genetic Study Uncovers Potential Therapy-Actionable Transcription Factors in MDS

Latest News

FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage SCLC 

The Food and Drug Administration (FDA) has granted accelerated approval to tarlatamab-dlle (Imdelltra) for certain patients with extensive stage small cell lung cancer (ES-SCLC).

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe